Skip to main content
. 2022 Dec 7;28:51–61. doi: 10.1016/j.omtm.2022.12.004

Figure 1.

Figure 1

Diagram of patients included in the study

Our study included patients from the expansion doses of two CAR T cell dose-escalation trials: one involving anti-CD22 CAR T cells and one involving bispecific anti-CD19/CD22 CAR T cells. (A) depicts patients in the CD22 cohort and (B) depicts patients in the CD19/22 cohort.